Therefore, rosuvastatin was used as an intervention factor to observe the changes of serum RBP4, hs-CRP, and IL-27 levels in patients with CHD after rosuvastatin treatment, so as to analyze the correlation and provide a new medical basis for disease control. Here, RBP4 is linked to coronary artery disorder.